These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 15990258)

  • 1. Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.
    Messaouik D; Sautou-Miranda V; Bagel-Boithias S; Chopineau J
    Int J Pharm; 2005 Aug; 299(1-2):65-72. PubMed ID: 15990258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor administration via nasogastric tube in pediatric practice: comparative analysis with protocol optimization.
    Ponrouch MP; Sautou-Miranda V; Boyer A; Bourdeaux D; Montagner A; Chopineau J
    Int J Pharm; 2010 May; 390(2):160-4. PubMed ID: 20132874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in vitro comparison of different providers to deliver four proton pump inhibitor products through a feeding tube.
    Devlin JW; Bakshi A; Bungay K; Olsen KM
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1603-11. PubMed ID: 17206948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
    Freston JW; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
    Park W; Hicks DM; Khandwala F; Richter JE; Abelson TI; Milstein C; Vaezi MF
    Laryngoscope; 2005 Jul; 115(7):1230-8. PubMed ID: 15995512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Several points that should be noticed during PPI treatment for peptic ulcers in elderly patients].
    Kinoshita Y; Fujishiro H; Amano Y; Adachi K
    Nihon Rinsho; 2002 Aug; 60(8):1606-12. PubMed ID: 12187759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    Thitiphuree S; Talley NJ
    Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori.
    Wang X; Fang JY; Lu R; Sun DF
    Digestion; 2006; 73(2-3):178-86. PubMed ID: 16837803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels.
    Di Mario F; Ingegnoli A; Altavilla N; Cavallaro LG; Bertolini S; Merli R; Cavestro GM; Iori V; Maino M; Leandro G; Franzè A
    Fundam Clin Pharmacol; 2005 Aug; 19(4):497-501. PubMed ID: 16011738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
    Dohmen W; Fuchs W
    MMW Fortschr Med; 2005 Apr; 147 Suppl 1():21-5. PubMed ID: 16739368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM; Gerrity MS; Anderson T
    Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasogastric omeprazole: effects on gastric pH in critically Ill patients.
    Balaban DH; Duckworth CW; Peura DA
    Am J Gastroenterol; 1997 Jan; 92(1):79-83. PubMed ID: 8995942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of proton pump inhibitors (PPIs) on wound healing of gastric mucosal cell injury].
    Masaoka T; Suzuki H; Ishii H
    Nihon Rinsho; 2004 Mar; 62(3):556-60. PubMed ID: 15038103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once or twice daily doses of proton pump inhibitor in treating Barrett's esophagus?
    Savarino V; Mela GS; Zentilin P; Celle G; Vigneri S
    Am J Gastroenterol; 1995 May; 90(5):845-6. PubMed ID: 7733108
    [No Abstract]   [Full Text] [Related]  

  • 16. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
    Horn JR; Howden CW
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():20-4. PubMed ID: 16303033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative method for administering proton-pump inhibitors through nasogastric tubes.
    Peckman HJ
    Am J Health Syst Pharm; 1999 May; 56(10):1020. PubMed ID: 10365730
    [No Abstract]   [Full Text] [Related]  

  • 18. Gastroesophageal reflux disease: new treatments.
    Katz PO
    Rev Gastroenterol Disord; 2002; 2(2):66-74. PubMed ID: 12122962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules.
    Hoover A; Sun D; Wen H; Jiang W; Cui M; Jiang X; Keire D; Guo C
    J Pharm Sci; 2017 Jul; 106(7):1859-1864. PubMed ID: 28416417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration.
    Ren P; Cui M; Anand O; Xia L; Zhao ZJ; Sun D; Sharp T; Conner DP; Peters J; Jiang W; Stier E; Jiang X
    AAPS J; 2017 Nov; 19(6):1593-1599. PubMed ID: 28879628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.